What are the commonly used P‑glycoprotein (P‑gp) inhibitors, their dosing regimens, and key contraindications?

P-glycoprotein (P-gp) Inhibitors in Clinical Practice

The most clinically relevant P-gp inhibitors in cardiovascular medicine are dronedarone (strong), verapamil (potent), quinidine (moderate), and amiodarone (moderate), with specific dosing adjustments required when combined with P-gp substrate drugs like dabigatran and edoxaban. 1, 2

Commonly Used P-gp Inhibitors by Potency

Strong P-gp Inhibitors

• Dronedarone: This antiarrhythmic doubles dabigatran plasma concentrations when administered simultaneously. Generally avoid combining dronedarone with all DOACs 1. If unavoidable, administer dronedarone 2 hours after DOAC administration to reduce interaction, though this remains suboptimal 1.

Potent P-gp Inhibitors

• Verapamil: Produces the most dramatic interactions depending on formulation 2:

  • Immediate-release verapamil taken within 1 hour before dabigatran: up to 180% increase in dabigatran levels
  • Slow-release verapamil: 60% increase in dabigatran concentration
  • Use dabigatran 110 mg BID (lower dose) when combining with verapamil 2
  • Space administration ≥2 hours apart to minimize interaction, though this is difficult to guarantee in practice 2
  • For edoxaban: 40% increase noted but not considered clinically significant per European label; use caution with additional risk factors 2

• Diltiazem: Less potent P-gp inhibitor than verapamil 1

  • 40% increase in apixaban plasma concentrations (caution warranted) 2
  • Does not significantly increase apixaban to dangerous levels and may be more suitable than verapamil in some circumstances 1
  • Does not impair warfarin clearance appreciably 1

Moderate P-gp Inhibitors

• Quinidine: Modestly increases edoxaban and dabigatran plasma concentrations 1

  • In high-risk patients (impaired renal function or concurrent P-gp inhibitor use), consider warfarin instead of dabigatran or edoxaban 1
  • Also weak CYP3A4 inhibitor; monitor INR more frequently when initiating with warfarin 1

• Amiodarone: Less potent than dronedarone 1

  • 40% increase in edoxaban AUC with normal renal function 2
  • Can be co-administered with DOACs if no other risk factors for DOAC accumulation exist (preserved renal function, no concurrent P-gp inhibitors) 1
  • For warfarin: increases levels proportional to amiodarone dose; mean INR increases from 2.6 to 3.1, requiring average 25% warfarin dose reduction 1

Azole Antifungals

• Itraconazole: IC₅₀ ~2 μM (potent inhibitor) 3
• Ketoconazole: IC₅₀ ~6 μM (moderate inhibitor) 3
• Fluconazole: No P-gp inhibition effect 3

Key Contraindications and Clinical Scenarios

Absolute Contraindications (Red Flags)

• Dronedarone + any DOAC: Avoid this combination 1
• Verapamil + dabigatran in patients with:
  • Impaired renal function
  • Concurrent use of another P-gp inhibitor
  • Age >75 with additional bleeding risk factors

Relative Contraindications (Use Alternative)

• Multiple P-gp inhibitors simultaneously: The effects compound 1, 2
• Moderate CYP3A4/P-gp inhibitors + rivaroxaban in renal dysfunction: AUC increases 76% in mild and 99% in moderate renal impairment 1
• Quinidine + dabigatran/edoxaban in high-risk patients: Switch to warfarin 1

Clinical Decision Algorithm

When prescribing P-gp substrate drugs (dabigatran, edoxaban, rivaroxaban, digoxin):

1. Identify all P-gp inhibitors the patient is taking (antiarrhythmics, calcium channel blockers, azoles)

2. Assess renal function: P-gp inhibitors have greater effect with renal dysfunction since P-gp mediates active renal secretion 1

3. Count bleeding risk factors: Age >75, weight <60 kg, prior bleeding, concurrent antiplatelet therapy

4. Apply color-coded risk stratification 2:

   • Red (contraindicated): Strong CYP3A4 and/or P-gp inhibitor combinations
   • Orange: Consider dose adjustment or different NOAC with moderate inhibitors
   • Yellow: If ≥2 yellow factors present, consider dose adjustment or alternative NOAC
   • White: No relevant interaction

5. Make specific adjustments:

   • Verapamil + dabigatran → Use 110 mg BID dose
   • Amiodarone + warfarin → Reduce warfarin dose by ~25%
   • Multiple moderate inhibitors → Choose alternative anticoagulant or reduce DOAC dose

Critical Pitfalls to Avoid

• Don't assume all calcium channel blockers behave identically: Verapamil is far more potent than diltiazem as a P-gp inhibitor 1, 2

• Formulation matters: Immediate-release verapamil has 3× greater effect than slow-release 2

• Plasma level changes ≠ clinical outcomes: Post-hoc ROCKET-AF analysis showed moderate CYP3A4/P-gp inhibitors were safe with rivaroxaban vs. warfarin when renal function preserved 1

• Polypharmacy amplifies risk: Even "mild" inhibitors become problematic when combined with other P-gp inhibitors or in patients with renal impairment 2

• Timing of administration can mitigate but not eliminate risk: 2-hour separation reduces but doesn't abolish verapamil-dabigatran interaction 2